Paclitaxel antitumor effect improvement in lung cancer and prevention of the painful neuropathy using large pegylated cationic liposomes
MetadataShow full item record
AuthorJiménez López, Julia; Bravo Caparrós, Inmaculada; Cabeza, Laura; Nieto López, Francisco Rafael; Ortiz, Raúl; Perazzoli, Gloria; Fernández Segura, Eduardo; Cañizares García, Francisco Javier; Baeyens Cabrera, José Manuel; Melguizo Alonso, Consolación; Prados Salazar, José Carlos
Elsevier France-Editions Scientifiques Medicales
Lung cancerPaclitaxelPegylated liposomesPeripheral neurotoxicityDorsal root ganglia
Jiménez-López, J., Bravo-Caparrós, I., Cabeza, L., Nieto, F. R., Ortiz, R., Perazzoli, G., ... & Prados, J. (2021). Paclitaxel antitumor effect improvement in lung cancer and prevention of the painful neuropathy using large pegylated cationic liposomes. Biomedicine & Pharmacotherapy, 133, 111059. [https://doi.org/10.1016/j.biopha.2020.111059]
SponsorshipJunta de Andalucía P11-CTS-7649 PI-0102-2017 P18-TP-3882 CTS-107; CTS-107 Group; Instituto de Salud Carlos III PI19/01478
Paclitaxel (PTX), a drug widely used in lung cancer, has serious limitations including the development of peripheral neurotoxicity, which may lead to treatment discontinuation and therapy failure. The transport of PTX in large cationic liposomes could avoid this undesirable effect, improving the patient’s prognosis. PTX was encapsulated in cationic liposomes with two different sizes, MLV (180-200 nm) and SUV (80-100 nm). In both cases, excellent biocompatibility and improved internalization and antitumor effect of PTX were observed in human and mice lung cancer cells in culture, multicellular spheroids and cancer stem cells (CSCs). In addition, both MLV and SUV with a polyethylene glycol (PEG) shell, induced a greater tumor volume reduction than PTX (56.4 % and 57.1 % vs. 36.7 %, respectively) in mice. Interestingly, MLV-PEG-PTX did not induce either mechanical or heat hypersensitivity whereas SUV-PEG-PTX produced a similar response to free PTX. Analysis of PTX distribution showed a very low concentration of the drug in the dorsal root ganglia (DRG) with MLV-PEG-PTX, but not with SUV-PEG-PTX or free PTX. These results support the hypothesis that PTX induces peripheral neuropathy by penetrating the endothelial fenestrations of the DRG (80-100 nm, measured in mice). In conclusion, our larger liposomes (MLV-PEG-PTX) not only showed biocompatibility, antitumor activity against CSCs, and in vitro and in vivo antitumor effect that improved PTX free activity, but also protected from PTX-induced painful peripheral neuropathy. These advantages could be used as a new strategy of lung cancer chemotherapy to increase the PTX activity and reduce its side effects.